{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:41:37Z","timestamp":1762504897107},"publisher-location":"Chichester, UK","reference-count":156,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd002130","type":"reference-entry","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T03:33:39Z","timestamp":1069385619000},"source":"Crossref","is-referenced-by-count":18,"title":["Platelet glycoprotein IIb\/IIIa blockers for percutaneous coronary intervention and the initial treatment of non-ST segment elevation acute coronary syndromes"],"prefix":"10.1002","author":[{"given":"Xavier","family":"Bosch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Loma-Osorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Marrugat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,10,23]]},"reference":[{"issue":"14","key":"10.1002\/14651858.CD002130-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/01.CIR.0000126284.40075.98","article-title":"Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone","volume":"109","author":"Antoniucci","year":"2004","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","article-title":"A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction","volume":"42","author":"Antoniucci","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB4|cit3","first-page":"178","article-title":"The ADMIRAL study: abciximab with percutaneous transluminal coronary angioplasty and stent in acute myocardial infarction","volume":"138","author":"Montalescot","year":"1999","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB5|cit4","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1093\/eurheartj\/ehi620","article-title":"Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study","volume":"26","author":"Montalescot","year":"2005","journal-title":"European Heart Journal"},{"issue":"25","key":"10.1002\/14651858.CD002130-BIB3|cit5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB6|cit6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jacc.2004.03.042","article-title":"The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial","volume":"44","author":"Valgimigli","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD002130-BIB7|cit7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","article-title":"Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction","volume":"346","author":"Stone","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002130-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/01.CIR.0000087601.45803.86","article-title":"Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial","volume":"108","author":"Tcheng","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD002130-BIB9|cit9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1161\/01.CIR.94.5.899","article-title":"Platelet membrane receptor glycoprotein IIb\/IIIa antagonism in unstable angina. The Canadian Lamifiban Study","volume":"94","author":"Theroux","year":"1996","journal-title":"Circulation"},{"issue":"9063","key":"10.1002\/14651858.CD002130-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study","volume":"349","author":"Simoons","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB11|cit11","first-page":"8","article-title":"Safety and efficacy of the platelet glycoprotein IIb\/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty","volume":"63","author":"Chen","year":"2000","journal-title":"Chinese Medical Journal (Taipei)"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB12|cit12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/eurheartj\/ehi071","article-title":"Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb\/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis","volume":"26","author":"Claeys","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehl004","article-title":"A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial","volume":"27","author":"Rasoul","year":"2006","journal-title":"European Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD002130-BIB14|cit14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"8902","key":"10.1002\/14651858.CD002130-BIB15|cit15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","article-title":"Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators","volume":"343","author":"Topol","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB16|cit16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.278.6.479","article-title":"Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb\/IIIa Inhibition for Prevention of Ischemic Complication","volume":"278","author":"Topol","year":"1997","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002130-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.99.15.1951","article-title":"Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb\/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb\/IIIa blockade","volume":"99","author":"Lincoff","year":"1999","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/14651858.CD002130-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators","volume":"336","author":"Topol","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002130-BIB19|cit19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199907293410503","article-title":"Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb\/IIIa receptors. Evaluation of Platelet IIb\/IIIa Inhibition in Stenting Investigators","volume":"341","author":"Lincoff","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"9122","key":"10.1002\/14651858.CD002130-BIB20|cit20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)85010-1","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting","volume":"352","author":"Topol","year":"1998","journal-title":"Lancet"},{"issue":"9195","key":"10.1002\/14651858.CD002130-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","article-title":"Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial","volume":"354","author":"Topol","year":"1999","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB22|cit22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/01.CIR.100.8.799","article-title":"Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)","volume":"100","year":"1999","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD002130-BIB23|cit23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.287.5.618","article-title":"Long-term efficacy of platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention","volume":"287","author":"O'Shea","year":"2002","journal-title":"JAMA"},{"issue":"19","key":"10.1002\/14651858.CD002130-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1001\/jama.285.19.2468","article-title":"Platelet glycoprotein IIb\/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial: a randomized controlled trial","volume":"285","author":"O'Shea","year":"2001","journal-title":"JAMA"},{"issue":"9247","key":"10.1002\/14651858.CD002130-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial","volume":"356","author":"Tcheng","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD002130-BIB26|cit26","first-page":"639","article-title":"Usefulness of platelet glycoprotein IIb\/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome","volume":"44","author":"Galassi","year":"1999","journal-title":"Cardiologia"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB27|cit27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/01.CIR.0000046487.06811.5E","article-title":"Long-term results after the glycoprotein IIb\/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial","volume":"107","author":"Ottervanger","year":"2003","journal-title":"Circulation"},{"issue":"9272","key":"10.1002\/14651858.CD002130-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1161\/01.CIR.91.8.2151","article-title":"Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb\/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators","volume":"91","author":"Tcheng","year":"1995","journal-title":"Circulation"},{"issue":"4A","key":"10.1002\/14651858.CD002130-BIB30|cit30","doi-asserted-by":"crossref","first-page":"29B","DOI":"10.1016\/S0002-9149(97)00574-2","article-title":"Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis","volume":"80","author":"Kleiman","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"9063","key":"10.1002\/14651858.CD002130-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II","volume":"349","author":"Tcheng","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB32|cit32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0735-1097(99)00635-X","article-title":"Effect of glycoprotein IIb\/IIIa receptor blockade with Abciximab on clinical and angiographic reestenosis after replacement of coronary stent following an acute myocardial infarction","volume":"35","author":"Neumann","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002130-BIB34|cit34","series-title":"European Society of Cardiology Congress Vienna, Austria ID=224","article-title":"One-year clinical outcomes in the ISAR-REACT 2 trial, a randomized comparison of abciximab versus placebo in patients with non-ST segment elevation acute coronary s\u00edndromes undergoing PCI after pretreatment with clopidogrel","author":"Seyfarth","year":"2007"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB35|cit35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","article-title":"A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel","volume":"350","author":"Kastrati","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002130-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/eurheartj\/ehi174","article-title":"One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel","volume":"26","author":"Sch\u00f6mig","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB37|cit37","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2796.2004.01398.x","article-title":"A randomized trial comparing phosphorylcholine-coated atenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries","volume":"256","author":"Hausleiter","year":"2004","journal-title":"Journal of Internal Mecicine"},{"key":"10.1002\/14651858.CD002130-BIB38|cit38","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0149-2918(02)80037-6","article-title":"A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement","volume":"24","author":"Juergens","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB40|cit40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0735-1097(95)00500-5","article-title":"Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb\/IIIa blockade in high risk patients undergoing coronary angioplasty","volume":"27","author":"Kereiakes","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"10.1002\/14651858.CD002130-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","article-title":"International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb\/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network","volume":"97","author":"Moliterno","year":"1998","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB42|cit42","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/hc0302.102573","article-title":"Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes","volume":"105","year":"2002","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB43|cit43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0002-8703(00)90031-0","article-title":"Patient-specific dosing of IIb\/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee","volume":"139","author":"Moliterno","year":"2000","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB44|cit44","series-title":"European Heart Journal","first-page":"448","article-title":"A randomized controlled trial of eptifibatide in patients presenting non-ST segment elevation acute myocardial infarction treated with an invasive strategy","author":"Durand","year":"2006"},{"key":"10.1002\/14651858.CD002130-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0002-9149(01)02041-0","article-title":"Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (The PRIDE Study)","volume":"88","author":"Tcheng","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD002130-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","article-title":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","volume":"338","author":"Bazzino","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD002130-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"Bazzino","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002130-BIB49|cit48","doi-asserted-by":"crossref","first-page":"34B","DOI":"10.1016\/S0002-9149(97)00575-4","article-title":"Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy","volume":"80","author":"Harrington","year":"1997","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB48|cit49","series-title":"Circulation","first-page":"I","article-title":"Glycoprotein IIb\/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event","author":"Harrington","year":"1998"},{"issue":"7","key":"10.1002\/14651858.CD002130-BIB50|cit50","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes","volume":"339","author":"Topol","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB51|cit51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB52|cit52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0735-1097(98)00192-2","article-title":"Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial.Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis","volume":"32","author":"Gibson","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD002130-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis","volume":"96","author":"Hanrath","year":"1997","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD002130-BIB54|cit54","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/01.CIR.94.9.2083","article-title":"Effects of integrelin, a platelet glycoprotein IIb\/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial","volume":"94","author":"Schulman","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD002130-BIB55|cit55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.89.2.596","article-title":"Randomized trial of a GPIIb\/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group","volume":"89","author":"Simoons","year":"1994","journal-title":"Circulation"},{"issue":"Suppl L","key":"10.1002\/14651858.CD002130-BIB56|cit56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/eurheartj\/16.suppl_L.36","article-title":"Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3)","volume":"16","author":"Brand","year":"1995","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD002130-BIB57|cit57","first-page":"72","article-title":"Prophylactic abciximab in elective coronary stenting: results of a randomized trial","volume":"14","author":"Tamburino","year":"2002","journal-title":"Journal of Invasive Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD002130-BIB58|cit58","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0735-1097(02)02014-4","article-title":"Effect of additional temporary glycoprotein IIb\/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR Trial)","volume":"40","author":"Bonz","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB59|cit59","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB60|cit60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ahj.2005.04.005","article-title":"Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial","volume":"150","author":"Roe","year":"2005","journal-title":"American Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0002-9149(99)00049-1","article-title":"Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb\/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy","volume":"83","author":"Alexander","year":"1999","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB62|cit62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2005.04.025","article-title":"Early abciximab administration in acute myocardial infarction treated with primary coronary intervention","volume":"108","author":"Bellandi","year":"2006","journal-title":"Internal Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB63|cit63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9149(97)00796-0","article-title":"Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial","volume":"81","author":"Blankenship","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB64|cit64","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1378\/chest.126.3.935","article-title":"Prehospital therapy with the platelet glycoprotein IIb\/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study","volume":"126","author":"Hanefeld","year":"2004","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD002130-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/0002-9149(94)90474-X","article-title":"Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications","volume":"74","author":"Boehrer","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB66|cit66","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0002-9149(99)00421-X","article-title":"Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial","volume":"84","author":"Brener","year":"1999","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD002130-BIB67|cit67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/01.CIR.97.4.340","article-title":"Randomized trial of an oral platelet glycoprotein IIb\/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction","volume":"97","author":"Cannon","year":"1998","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB68|cit68","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0002-9149(98)00519-0","article-title":"Usefulness of abciximab for treatment of early coronary artery stent thrombosis","volume":"82","author":"Casserly","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD002130-BIB69|cit69","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00001721-200206000-00002","article-title":"Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention","volume":"13","author":"Claeys","year":"2002","journal-title":"Blood Coagulation & Fibrinolysis"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB70|cit70","doi-asserted-by":"crossref","first-page":"401.e9","DOI":"10.1016\/j.ahj.2005.06.006","article-title":"Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study","volume":"150","author":"Leoncini","year":"2005","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD002130-BIB71|cit71","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jacc.2004.03.058","article-title":"Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb\/IIIa inhibition, in acute myocardial infarction","volume":"44","author":"Costantini","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB72|cit72","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0002-9149(03)00983-4","article-title":"Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction","volume":"92","author":"Cutlip","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1135.e11","DOI":"10.1016\/j.ahj.2005.02.015","article-title":"Effects of abciximab and preprocedural glycemic control in diabetic patients undergoing elective coronary stenting","volume":"149","author":"Luca","year":"2005","journal-title":"American Heart Journal"},{"issue":"15","key":"10.1002\/14651858.CD002130-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0195-668X(03)00259-8","article-title":"A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b\/3a upstream therapy and acute coronary syndromes","volume":"24","author":"'t Hof","year":"2003","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB75|cit75","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0002-8703(03)00447-2","article-title":"Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction","volume":"147","author":"Ercan","year":"2004","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB76|cit76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","article-title":"Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial","volume":"47","author":"Bolognese","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB77|cit77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9149(98)00238-0","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb\/IIIa Receptor Blockade","volume":"82","author":"Ghaffari","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S0735-1097(99)00038-8","article-title":"Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study","volume":"33","author":"Merkhof","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB79|cit79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2005.05.045","article-title":"Comparison of abciximab with 'high-dose' tirofiban in patients undergoing percutaneous coronary intervention","volume":"109","author":"Gunasekara","year":"2006","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein iib\/IIIa inhibition:the GUSTO V randomised trial","volume":"357","year":"2001","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD002130-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators","volume":"340","author":"Hamm","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"Suupl 5","key":"10.1002\/14651858.CD002130-BIB82|cit82","first-page":"V\/10","article-title":"Pre-hospital therapy of acute coronary syndrome with the glycoprotein-IIb\/IIIa receptor antagonist Eptifibatide - Pilot study Bochum","volume":"91","author":"Hanefeld","year":"2002","journal-title":"Zeitschrift Fur Kardiologie"},{"issue":"9192","key":"10.1002\/14651858.CD002130-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(99)10285-X","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management","volume":"354","author":"Heeschen","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB84|cit84","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.CIR.95.4.846","article-title":"Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb\/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators","volume":"95","author":"Ohman","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/eurheartj\/ehi293","article-title":"Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial","volume":"26","author":"Zeymer","year":"2005","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD002130-BIB86|cit86","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/01.CIR.96.4.1117","article-title":"Sustained platelet glycoprotein IIb\/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment","volume":"96","author":"Kereiakes","year":"1997","journal-title":"Circulation"},{"issue":"13","key":"10.1002\/14651858.CD002130-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.CIR.98.13.1268","article-title":"Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb\/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial","volume":"98","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD002130-BIB88|cit88","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1161\/01.CIR.97.9.857","article-title":"Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators","volume":"97","author":"Kereiakes","year":"1998","journal-title":"Circulation"},{"issue":"19","key":"10.1002\/14651858.CD002130-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1161\/01.CIR.97.19.1912","article-title":"Diabetes mellitus, glycoprotein IIb\/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators","volume":"97","author":"Kleiman","year":"1998","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD002130-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/01.CIR.98.14.1358","article-title":"Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)","volume":"98","author":"Klootwijk","year":"1998","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB91|cit91","series-title":"Annals of Hematology","first-page":"A53","article-title":"Fradafiban, a non-peptide GP IIB\/IIA antagonist during elective coronary angioplasty: safety and antiplatelet effects","author":"Krause","year":"1996"},{"issue":"12","key":"10.1002\/14651858.CD002130-BIB92|cit92","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0002-9149(96)00128-2","article-title":"Effects of platelet glycoprotein IIb\/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators","volume":"77","author":"Lefkovits","year":"1996","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB93|cit93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0195-668X(02)00322-6","article-title":"Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA.[see comment]","volume":"24","author":"Lenderink","year":"2003","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB94|cit94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0735-1097(97)00110-1","article-title":"Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb\/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3 in Preventing Ischemic Complications","volume":"30","author":"Lincoff","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD002130-BIB95|cit95","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/01.CIR.99.18.2371","article-title":"Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb\/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators","volume":"99","author":"Mahaffey","year":"1999","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD002130-BIB96|cit96","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9149(97)00589-4","article-title":"Effect of platelet glycoprotein IIb\/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb\/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications","volume":"80","author":"Mak","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"22","key":"10.1002\/14651858.CD002130-BIB97|cit97","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","article-title":"Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience","volume":"99","author":"McClure","year":"1999","journal-title":"Circulation"},{"issue":"4A","key":"10.1002\/14651858.CD002130-BIB98|cit98","doi-asserted-by":"crossref","first-page":"39B","DOI":"10.1016\/S0002-9149(97)00576-6","article-title":"Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes","volume":"80","author":"McElwee","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD002130-BIB99|cit99","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0002-9149(99)00437-3","article-title":"Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries","volume":"84","author":"Miller","year":"1999","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB100|cit100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijcard.2004.10.015","article-title":"Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: Comparison of prehospital tirofiban versus fibrinolysis before direct PCI","volume":"103","author":"Mockel","year":"2005","journal-title":"International Journal of Cardiology"},{"issue":"19","key":"10.1002\/14651858.CD002130-BIB101|cit101","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1001\/jama.286.19.2405","article-title":"Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.[see comment]","volume":"286","author":"Morrow","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD002130-BIB102|cit102","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.96.4.1130","article-title":"Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb\/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men","volume":"96","author":"Muller","year":"1997","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD002130-BIB103|cit103","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1097-0304(199710)42:2<173::AID-CCD16>3.0.CO;2-P","article-title":"Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome","volume":"42","author":"Murdock","year":"1997","journal-title":"Catheterization & Cardiovascular Diagnosis"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB104|cit104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0735-1097(98)00620-2","article-title":"The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb\/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications","volume":"33","author":"Narins","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"issue":"24","key":"10.1002\/14651858.CD002130-BIB105|cit105","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1161\/01.CIR.98.24.2695","article-title":"Effect of glycoprotein IIb\/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction","volume":"98","author":"Neumann","year":"1998","journal-title":"Circulation"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD002130-BIB106|cit106","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0002-8703(99)70104-3","article-title":"Long-term oral platelet glycoprotein IIb\/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee","volume":"138","author":"Newby","year":"1999","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB107|cit107","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","article-title":"Benefit of glycoproteoin IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD002130-BIB108|cit108","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ehj.2004.04.003","article-title":"Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b\/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.[see comment]","volume":"25","author":"van't Hof","year":"2004","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD002130-BIB109|cit109","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0735-1097(98)00474-4","article-title":"Combining thrombolysis with the platelet glycoprotein IIb\/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial","volume":"32","author":"Harrington","year":"1998","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB110|cit110","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","article-title":"Benefit of glycoproteoin IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. The PARAGON-B troponin substudy","volume":"103","author":"Newby","year":"2001","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB111|cit111","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1067\/mhj.2002.119762","article-title":"Abciximab improves 6-month clinical outcome after rescue coronary angioplasty","volume":"143","author":"Petronio","year":"2002","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB112|cit112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ccd.20456","article-title":"Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: results of a prospective randomized study","volume":"66","author":"Prati","year":"2005","journal-title":"Catheterization & Cardiovascular Interventions"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB113|cit113","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0002-9149(96)00749-7","article-title":"Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb\/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators","volume":"79","author":"Lincoff","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"23","key":"10.1002\/14651858.CD002130-BIB114|cit114","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.ehj.2004.09.018","article-title":"Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - Results of the Austrian multi-centre randomized ReoPro-BRIDGING Study","volume":"25","author":"Gyongyosi","year":"2004","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB115|cit115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIb\/IIIa blockade vs heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB116|cit116","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0002-8703(03)00517-9","article-title":"A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes","volume":"146","author":"Roe","year":"2003","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD002130-BIB117|cit117","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.CIR.96.1.76","article-title":"First chronic platelet glycoprotein IIb\/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions","volume":"96","author":"Simpfendorfer","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB118|cit118","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0735-1097(00)00923-2","article-title":"Facilitation of early percutaneous coronary intervention after Reteplase with or without abciximab in acute myocardial infarction","volume":"36","author":"Hermann","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB119|cit119","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ahj.2004.06.023","article-title":"Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction","volume":"149","author":"Steen","year":"2005","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB120|cit120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM200008103430602","article-title":"Coronary stenting plus platelet glycoprotein IIb\/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction","volume":"343","author":"Sch\u00f6mic","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002130-BIB121|cit121","first-page":"109","article-title":"1-year mortality after stenting with Abciximab or thrombolysis in acute myocardial infarction and prognostic value of myocardial salvage. Results of the STOPAMI study","volume":"90","author":"Schomig","year":"2001","journal-title":"Zeitschrift Fur Kardiologie"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002130-BIB122|cit122","first-page":"74","article-title":"Myocardial salvage and clinical one-year results in patients with acute anterior myocardial infarction and stent placement with Abciximab or thrombolysis: a STOPAMI sub-group analysis","volume":"90","author":"Schricke","year":"2001","journal-title":"Zeitschrift Fur Kardiologie"},{"key":"10.1002\/14651858.CD002130-BIB123|cit123","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0140-6736(02)08022-4","article-title":"Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial","volume":"359","author":"Kastrati","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB124|cit124","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1592\/phco.26.5.609","article-title":"Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention","volume":"26","author":"Summers","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD002130-BIB125|cit125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.103.13.1727","article-title":"Randomized trial of apirin, sibrafiban, or both for secondary prevention after acute coronary syndromes","volume":"103","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD002130-BIB126|cit126","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0735-1097(93)90041-X","article-title":"Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study","volume":"22","author":"Kleiman","year":"1993","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB127|cit127","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM200106213442502","article-title":"Comparison of two platelet glycoprotein IIb\/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization","volume":"344","author":"Topol","year":"2001","journal-title":"New Enland Journal of Medicine"},{"key":"10.1002\/14651858.CD002130-BIB128|cit128","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/eurheartj\/ehi432","article-title":"Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction","volume":"26","author":"Thiele","year":"2005","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD002130-BIB129|cit129","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1161\/01.CIR.0000056120.00513.7A","article-title":"Adjunctive platelet glycoprotein IIb\/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"21","key":"10.1002\/14651858.CD002130-BIB130|cit130","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1161\/01.CIR.99.21.2720","article-title":"Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators","volume":"99","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB131|cit131","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1067\/mhj.2000.107172","article-title":"First report of an intravenous and oral glycoprotein IIb\/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials","volume":"140","author":"Giugliano","year":"2000","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB132|cit132","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.293.17.2109","article-title":"Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial","volume":"293","author":"Valgimigli","year":"2005","journal-title":"JAMA"},{"issue":"21","key":"10.1002\/14651858.CD002130-BIB133|cit133","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/euhj.1999.1662","article-title":"Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial","volume":"20","author":"Brand","year":"1999","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB134|cit134","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S0735-1097(99)00038-8","article-title":"Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study","volume":"33","author":"Merkhof","year":"1999","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB135|cit135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/B:THRO.0000024054.53591.a8","article-title":"The effect of glycoprotein IIb\/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study","volume":"16","author":"Wong","year":"2003","journal-title":"Journal of Thrombosis & Thrombolysis"},{"key":"10.1002\/14651858.CD002130-BIB136|cit136","first-page":"II","article-title":"Randomised trial assessing efficacy and safety of cornaroplasty in coronary arteries of reference size of < 2,9 mm with the use of integrillin - eptifibatide -- preliminary results","volume":"57","author":"Zajdel","year":"2002","journal-title":"Kardiologia Polska"},{"issue":"15","key":"10.1002\/14651858.CD002130-BIB137|cit137","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1161\/01.CIR.100.15.1609","article-title":"Intracoronary thrombus and platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators","volume":"100","author":"Zhao","year":"1999","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD002130-BIB138|cit138","first-page":"279","article-title":"Stenting in chronic total occlusion of left anterior descending artery. Randomised comparison of the impact of adjunctive abciximab therapy on immediate and long-term results","volume":"10","author":"Gasior","year":"2003","journal-title":"Folia Cardiologica"},{"issue":"6","key":"10.1002\/14651858.CD002130-BIB139|cit139","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","article-title":"The early glycoprotein IIb\/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale","volume":"149","author":"Giugliano","year":"2005","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB140|cit140","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jacc.2007.02.028","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-elevation myocardial infarction- executive summary: a report of the American College of Cardiology\/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"50","author":"Anderson","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB141|cit141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"20","key":"10.1002\/14651858.CD002130-BIB142|cit142","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","article-title":"Platelet glycoprotein IIb\/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention","volume":"100","author":"Boersma","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB143|cit143","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB144|cit144","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002130-BIB145|cit145","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/archinte.166.18.2027","article-title":"Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes. Insights from the CRUSADE initiative","volume":"166","author":"Mehta","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002130-BIB146|cit146","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002130-BIB147|cit147","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/eurheartj\/ehm161","article-title":"Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology","volume":"28","author":"Bassand","year":"2007","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB148|cit148","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/euhj.2000.2305","article-title":"Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology\/American College of Cardiology Committee for the Redefinition of Myocardial Infarction","volume":"21","year":"2000","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002130-BIB149|cit149","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002130-BIB150|cit150","first-page":"147","article-title":"Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE)","volume":"97","author":"Fox","year":"2007","journal-title":"Heart"},{"key":"10.1002\/14651858.CD002130-BIB151|cit151","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets. Results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"issue":"4 Suppl S","key":"10.1002\/14651858.CD002130-BIB152|cit152","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0735-1097(02)02831-0","article-title":"Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention","volume":"41","author":"Mehta","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002130-BIB153|cit153","doi-asserted-by":"crossref","unstructured":"Robinson M Ginnelly L Sculpher MJ Jones L Riemsma R Palmer S A systematic review update of the clinical effectiveness and cost effectiveness of glycoprotein IIb\/IIIa antagonists Health Technology Assessment 2002","DOI":"10.3310\/hta6250"},{"key":"10.1002\/14651858.CD002130-BIB154|cit154","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002130-BIB155|cit155","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood.V71.4.831.831","article-title":"The platelet membrane glycoprotein IIb-IIIa complex","volume":"71","author":"Phillips","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD002130-BIB156|cit156","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/01.CIR.0000019581.22812.B2","article-title":"Platelet Glycoprotein IIb\/IIIa inhibitors. Recognition of a two-edge sword?","volume":"106","author":"Quin","year":"2002","journal-title":"Circulation"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:09:49Z","timestamp":1628543389000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002130"}},"subtitle":[],"editor":[{"given":"Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2001,10,23]]},"references-count":156,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002130","relation":{},"subject":[],"published":{"date-parts":[[2001,10,23]]}}}